object
increas
hepat
express
dipeptidyl
peptidas
associ
nonalcohol
fatti
liver
diseas
nafld
whether
caus
develop
nafld
yet
clarifi
investig
effect
hepat
overexpress
develop
liver
steatosi
mous
model
dietinduc
obes
method
plasma
activ
subject
without
nafld
analyz
wildtyp
wt
liverspecif
transgen
mice
fed
highfat
diet
character
bodi
weight
bodi
composit
hepat
fat
content
insulin
sensit
vitro
experi
cell
primari
mous
hepatocyt
conduct
valid
cell
autonom
effect
lipid
storag
insulin
sensit
result
subject
suffer
insulin
resist
nafld
show
increas
plasma
activ
compar
healthi
control
analysi
mice
reveal
elev
system
activ
diminish
activ
level
furthermor
show
increas
bodi
weight
fat
mass
adipos
tissu
inflamm
hepat
steatosi
liver
damag
hypercholesterolemia
effect
accompani
increas
express
pparg
well
sever
insulin
resist
liver
agreement
treatment
cell
primari
hepatocyt
physiolog
concentr
result
impair
insulin
sensit
independ
lipid
content
conclus
result
give
evid
elev
express
liver
promot
nafld
insulin
resist
link
reduc
level
activ
also
autoand
paracrin
effect
hepat
insulin
signal
abbrevi
ad
adenoviru
akt
akt
serineethreonin
protein
kinas
alt
alanin
aminotransferas
apob
apolipoprotein
b
ast
aspart
aminotransferas
bat
brown
adipos
tissu
fatti
acid
translocas
carnitin
palmitoyltransferas
diacylglycerol
oacyltransferas
dipeptidyl
peptidas
transgen
mice
hepatocytespecif
overexpress
adhes
g
proteincoupl
receptor
gfp
green
fluoresc
protein
ggt
gammaglutamyl
transpeptidas
glucagonlik
peptid
gwat
gonad
white
adipos
tissu
hfd
highfat
diet
homair
homeostat
model
assess
insulin
resist
interleukin
mapk
mitogenactiv
protein
kinas
chemokin
cc
motif
ligand
monoacylglycerol
oacyltransferas
nafld
nonalcohol
fatti
liver
diseas
nash
nonalcohol
steatohepat
nfkb
nuclear
factorkb
pakt
phosphoryl
akt
serineethreonin
protein
kinas
wt
wildtyp
pparg
peroxisom
prolifer
activ
receptor
gamma
recombin
human
dipeptidyl
peptidas
recombin
mous
dipeptidyl
peptidas
sm
skelet
muscl
sterol
regulatori
element
bind
transcript
factor
swat
subcutan
white
adipos
tissu
tnfa
tumor
necrosi
factor
nonalcohol
fatti
liver
diseas
nafld
character
excess
deposit
fat
steatosi
liver
classifi
two
major
clinicalhistolog
subgroup
nonalcohol
fatti
liver
nafl
ii
nonalcohol
steatohepat
nash
preval
nafld
gener
adult
popul
rang
rise
increas
incid
obes
type
diabet
patient
nash
reveal
augment
mortal
rate
wherea
nafl
link
increas
risk
type
diabet
current
manag
nafld
includ
lifestyl
modif
control
metabol
risk
factor
pharmacolog
therapi
howev
sinc
biopsyproven
nash
patient
receiv
medic
treatment
need
suitabl
drug
treatment
nafl
dipeptidyl
peptidas
could
serv
target
nafl
therapi
serin
proteas
cleav
varieti
substrat
includ
incretin
hormon
chemokin
growth
factor
neuropeptid
ubiquit
express
apic
surfac
mani
cell
type
also
occur
solubl
form
circul
bodi
fluid
accumul
evid
involv
develop
chronic
liver
diseas
highli
express
liver
express
well
circul
level
increas
nafl
nash
suggest
biomark
nafld
shown
valid
measur
hepatocyt
apoptosi
fibrosi
genet
ablat
mice
rat
result
improv
insulin
sensit
liver
function
pharmacolog
inhibit
caus
reduct
hepat
steatosi
improv
insulin
sensit
mous
model
obes
diabet
besid
role
degrad
incretin
hormon
shown
exert
incretinindepend
function
induct
insulin
resist
inflamm
differ
cellular
system
howev
whether
elev
particular
hepat
trigger
insulin
resist
nafld
simpli
reflect
state
liver
diseas
entir
clarifi
recent
demonstr
dietinduc
obes
mice
express
releas
substanti
increas
liver
compar
adipos
depot
show
elev
express
liver
mice
associ
earli
insulin
resist
turn
trigger
later
liver
steatosi
current
studi
analyz
activ
plasma
healthi
nafld
subject
elucid
effect
hepatocytespecif
overexpress
develop
insulin
resist
liver
steatosi
mice
obes
condit
quantif
plasma
activ
subject
prediabet
ongo
famili
tuef
studi
type
diabet
select
particip
underw
standard
point
oral
glucos
toler
test
g
glucos
overnight
fast
period
venou
blood
sampl
obtain
time
point
min
measur
glucos
advia
chemistri
analyz
siemen
healthcar
diagnost
insulin
advia
centaur
xp
immunoassay
system
siemen
healthcar
diagnost
insulin
sensit
calcul
composit
wholebodi
insulin
sensit
index
isi
liver
fat
quantifi
local
spectroscopi
use
mr
scanner
magnetom
sonata
siemen
healthcar
cohort
divid
quartil
accord
liver
fat
content
quantif
plasma
activ
sampl
subject
first
fourth
quartil
match
age
sex
use
activ
measur
ml
plasma
describ
work
describ
carri
accord
code
ethic
world
medic
associ
declar
helsinki
hepatocytespecif
transgen
mice
gener
compani
genoway
lyon
franc
via
hprt
hypoxanthin
phosphoribosyltransferas
target
transgenesi
knockin
target
vector
contain
murin
cdna
control
albumin
promot
transfect
es
cell
inject
blastocyst
obtain
chimera
backcross
seven
time
mice
threeweekold
male
mice
n
wildtyp
wt
n
litterm
receiv
highfat
diet
hfd
blood
glucos
bodi
weight
bodi
composit
liver
fat
content
bodi
weight
measur
everi
week
blood
glucos
measur
use
contour
xt
glucomet
bayer
week
age
bodi
composit
liver
fat
content
analyz
use
nuclear
magnet
reson
comput
tomographi
ct
describ
nonfast
mice
intraperiton
inject
insulin
iukg
bodi
weight
actrapid
penfil
novo
nordisk
blood
glucos
level
measur
indic
time
point
plasma
insulin
concentr
quantifi
vena
cava
blood
use
mous
ultrasensit
insulin
elisa
alpco
plasma
adiponectin
leptin
level
measur
mous
r
system
mouserat
leptin
r
system
elisa
kit
activ
level
detect
oral
glucos
administr
use
activ
elisa
kit
shibayagi
mice
fast
h
oral
administ
glucos
mgg
bodi
weight
euthan
min
isofluran
follow
blood
taken
edtaco
syring
supplement
mlml
inhibitor
cat
millipor
either
vena
cava
vena
porta
plasma
triglycerid
sigma
free
fatti
acid
wako
cholesterol
human
alt
human
ast
human
ggt
human
level
measur
accord
manufactur
protocol
solubl
concentr
determin
use
mous
elisa
kit
r
system
plasma
activ
measur
convers
glycinprolinpnitroanilid
sigma
pnitroanilid
twenti
ml
plasma
ml
cell
supernat
ml
cell
homogen
fill
ml
assay
buffer
mmoll
glycin
mmoll
edta
ph
supplement
ml
glycineprolinepnitroanilid
mmoll
product
pnitroanilid
measur
absorb
nm
kinet
measur
c
activ
sampl
calcul
use
pnitroanilin
sigma
standard
curv
concentr
rang
mmoll
result
express
nmolminml
liver
glycogen
cholesterol
triglycerid
content
liver
glycogen
content
analyz
use
glucos
colorimetr
assay
human
subsequ
amyloglucosidas
fluka
digest
liver
homogen
hepat
triglycerid
content
measur
describ
use
kit
randox
liver
cholesterol
level
determin
use
commerci
kit
human
western
blot
perform
describ
incub
primari
antibodi
supplementari
tabl
perform
c
overnight
secondari
antibodi
peroxidas
label
supplementari
tabl
quantif
blot
perform
use
imagej
softwar
rel
aktphosphoryl
untreat
insulinstimul
control
set
liver
adipos
tissu
fix
formaldehyd
embed
paraffin
hematoxylin
eosin
h
e
siriu
red
trichrom
stain
liver
section
perform
use
standard
protocol
neutral
lipid
stain
cryo
section
use
oil
red
immunohistochem
stain
paraffin
embed
section
deparaffin
incub
appropri
antibodi
supplementari
tabl
c
overnight
secondari
antibodi
either
label
biotinyl
supplementari
tabl
iodid
invitrogen
use
nuclei
stain
microscopi
perform
confoc
laser
scan
microscop
leica
microsystem
keyenc
fluoresc
microscop
keyenc
intern
quantit
realtim
pcr
microarray
analysi
total
rna
extract
cdna
synthesi
taqman
gene
express
assay
perform
describ
previous
liver
transcriptom
analysi
perform
compani
oaklab
berlin
germani
describ
cell
cultur
human
hepatoma
cell
cultur
c
co
dulbecco
modifi
eagl
medium
dmem
contain
mmoll
glucos
fetal
calf
serum
fc
nonessenti
amino
acid
neaa
cell
treat
variou
concentr
recombin
human
r
system
h
serumstarv
h
insulinstimul
min
nmoll
primari
hepatocyt
isol
standard
diet
fed
male
wt
mice
collagenas
perfus
method
isol
hepatocyt
cultur
well
plate
dmem
mmoll
glucos
fc
neaa
penicillinstreptomycin
c
co
h
cell
either
infect
pfuwel
adenoviru
code
fulllength
murin
green
fluoresc
protein
gfp
adgfp
vector
biolab
treat
ngml
recombin
mous
r
system
cell
cultur
h
serumstarv
h
subsequ
stimul
insulin
min
nmoll
statist
analysi
data
display
mean
ae
sem
comparison
two
group
student
onetail
applic
twotail
unpair
ttest
use
analysi
fold
chang
wilcoxon
sign
rank
test
perform
comparison
group
oneway
analysi
varianc
anova
follow
tukey
multipl
comparison
test
use
analysi
time
cours
twoway
anova
bonferroni
multipl
comparison
test
use
calcul
perform
graphpad
prism
softwar
signific
level
set
pvalu
less
recent
shown
individu
elev
level
hepat
steatosi
show
increas
express
liver
liver
substanti
contribut
circul
level
analyz
plasma
activ
nafld
patient
prediabet
comparison
ageand
sexmatch
healthi
control
expect
nafld
subject
reveal
increas
liver
fat
content
figur
reduc
insulin
sensit
figur
activ
augment
plasma
nafld
patient
figur
ae
vs
ae
p
indic
increas
releas
enzym
circul
howev
bmi
also
higher
nafld
group
ae
vs
ae
p
increas
plasma
activ
could
also
origin
elev
adipos
tissu
mass
liverspecif
overexpress
result
elev
plasma
activ
diminish
level
investig
whether
elev
level
fatti
liver
caus
consequ
diseas
gener
transgen
mous
model
hepatocytespecif
overexpress
male
wildtyp
wt
mice
receiv
hfd
kcal
fat
week
sacrif
week
age
mrna
protein
content
significantli
increas
respect
liver
mice
alter
adipos
depot
skelet
muscl
figur
b
primari
hepatocyt
isol
mice
also
show
elev
protein
content
cellular
activ
isol
wt
anim
figur
supplementari
figur
b
moreov
compar
endogen
level
differ
metabol
tissu
wt
mice
reveal
highest
express
liver
figur
b
immunohistochem
stain
liver
section
suggest
increas
membran
local
mice
indic
costain
plasma
membran
marker
ecadherin
plasma
activ
c
ageand
sexmatch
subject
without
control
nafld
data
repres
mean
ae
sem
n
onetail
ttest
perform
test
whether
liver
fat
insulin
sensit
index
plasma
activ
increas
nafld
subject
p
p
figur
transmembran
bound
shed
hepatocyt
studi
capac
releas
analyz
plasma
activ
wt
mice
anim
exhibit
increas
plasma
activ
demonstr
elev
releas
liver
mice
figur
addit
cell
supernat
primari
hepatocyt
mice
show
higher
concentr
activ
wt
control
supplementari
figur
sinc
incretin
hormon
known
substrat
next
analyz
effect
hepat
overexpress
halflif
glucagonlik
peptid
fifteen
minut
oral
glucos
gavag
portal
vein
concentr
activ
form
similar
wt
anim
indic
differ
secret
intestin
lcell
figur
howev
analysi
blood
obtain
vena
cava
liver
passag
reveal
reduct
activ
mice
suggest
increas
cleavag
inactiv
hepatocyt
origin
figur
togeth
data
indic
hepat
overexpress
result
elev
plasma
activ
turn
lead
reduc
postprandi
level
elev
hepat
activ
lead
increas
fat
mass
adipos
tissu
inflamm
phenotyp
character
hfd
fed
mice
reveal
increas
bodi
weight
gain
due
elev
fat
mass
rather
chang
lean
mass
figur
week
age
mass
white
brown
adipos
tissu
significantli
increas
mice
figur
plasma
triglycerid
free
fatti
acid
concentr
differ
cholesterol
level
elev
mice
liverspecif
overexpress
tabl
sinc
obes
associ
adipos
tissu
inflamm
next
analyz
express
inflammatori
marker
gonad
white
adipos
tissu
inde
express
macrophag
marker
proinflammatori
cytokin
tnfa
tnf
increas
white
adipos
tissu
mice
figur
agreement
immunohistochem
stain
show
higher
abund
macrophag
adipos
tissu
anim
figur
investig
whether
increas
express
liver
lead
hepat
steatosi
consequ
elev
lipid
accumul
studi
develop
fatti
liver
wt
mice
comput
tomographi
young
age
week
wt
mice
show
low
liver
fat
content
figur
howev
week
hfd
feed
hepat
fat
content
rais
ae
mice
wherea
liver
fat
content
wt
mice
unchang
ae
figur
addit
week
diet
liver
fat
content
reach
ae
ae
wt
mice
p
figur
indic
slow
direct
effect
hepat
level
liver
steatosi
week
age
liver
glycogen
liver
cholesterol
significantli
differ
wherea
level
triglycerid
higher
mice
figur
consequ
liver
weight
show
tendenc
higher
wt
mice
figur
b
histolog
examin
confirm
increas
accumul
ectop
fat
figur
larger
lipid
droplet
indic
stain
lipid
droplet
coat
protein
perilipin
liver
mice
figur
plasma
analysi
marker
liver
damag
show
significantli
elev
level
gammaglutamyl
transpeptidas
ggt
p
numer
increas
alanin
aminotransferas
alt
p
aspart
aminotransferas
ast
p
level
tabl
howev
marker
inflamm
fibrosi
similar
liver
wt
anim
supplementari
figur
taken
togeth
elev
level
liver
caus
hepat
steatosi
indic
liver
damag
inflamm
fibrosi
mice
hfd
next
perform
global
transcriptom
profil
rna
isol
liver
wt
mice
microarray
analysi
reveal
gene
upand
gene
downregul
liver
mice
chang
j
p
focus
gene
involv
lipid
metabol
detect
chang
gene
triglycerid
hydrolysi
de
novo
lipogenesi
except
slightli
elev
mrna
level
apob
mice
supplementari
figur
strike
effect
observ
transcript
factor
peroxisom
prolifer
activ
receptor
gamma
pparg
downstream
target
fatti
acid
translocas
significantli
increas
liver
mice
supplementari
figur
monoacylglycerol
oacyltransferas
anoth
target
gene
hepatocyt
pparg
also
tend
higher
mice
supplementari
figur
valid
use
quantit
realtim
pcr
confirm
significantli
elev
express
pparg
trend
toward
higher
level
transgen
anim
figur
agreement
western
blot
analysi
show
higher
pparg
protein
level
liver
anim
figur
interestingli
pparg
isoform
upregul
sampl
suggest
isoformspecif
effect
pparg
express
summari
liver
steatosi
associ
elev
hepat
pparg
express
recent
shown
earli
alter
hepat
associ
insulin
resist
result
later
liver
steatosi
studi
primari
human
adipocyt
skelet
muscl
cell
discov
direct
effect
solubl
insulin
sensit
cell
test
whether
elev
level
also
affect
hepat
insulin
sensit
human
cell
treat
variou
concentr
recombin
human
analyz
insulin
respons
insulinstimul
aktphosphoryl
unaffect
low
dose
ng
ml
complet
blunt
dosag
ngml
figur
also
primari
murin
hepatocyt
obtain
lean
wt
mice
ngml
recombin
mous
reduc
insulinstimul
aktphosphoryl
figur
moreov
adenoviralmedi
overexpress
fulllength
primari
hepatocyt
led
reduct
insulin
sensit
compar
adgfp
infect
control
cell
figur
primari
hepatocyt
obtain
standard
diet
fed
wt
mice
differ
lipid
content
data
shown
reveal
differ
insulin
respons
hepatocyt
mice
show
lower
aktphosphoryl
wt
control
figur
taken
togeth
solubl
reduc
insulin
sensit
human
mous
liver
cell
suggest
direct
role
hepat
insulin
signal
test
hepat
insulin
sensit
wt
mice
inject
insulin
anim
sacrif
min
later
figur
show
insulinstimul
aktphosphoryl
markedli
lower
liver
mice
compar
wt
litterm
agreement
insulin
toler
test
week
age
confirm
impair
insulin
sensit
mice
figur
howev
timepoint
fatti
liver
alreadi
induc
figur
fast
insulin
level
well
homair
homeostat
model
assess
insulin
resist
numer
increas
mice
reach
statist
signific
tabl
final
consid
leptin
adiponectin
ratio
anoth
measur
system
insulin
resist
found
increas
ratio
mice
week
age
tabl
thu
overexpress
liver
dietinduc
obes
mice
impair
hepat
insulin
sensit
present
data
demonstr
subject
suffer
nafld
exhibit
elev
plasma
activ
ii
hepatocytespecif
overexpress
contribut
elev
plasma
activ
enzym
turn
caus
diminish
glucoseinduc
activ
level
moreov
overexpress
liver
iii
promot
develop
hepat
insulin
resist
nafld
iv
enhanc
adipos
tissu
expans
inflamm
obes
condit
nafld
patient
known
increas
mrna
level
liver
associ
degre
hepat
steatosi
obes
subject
addit
recent
shown
obesitypron
mice
reveal
increas
express
alreadi
age
week
proceed
hepat
steatosi
later
life
howev
clear
whether
elev
level
liver
causal
later
onset
nafld
show
first
time
overexpress
hepatocyt
hfd
fed
mice
promot
develop
fatti
liver
thu
dysregul
express
eg
epigenet
mechan
lead
perturb
hepat
metabol
final
elev
ectop
lipid
accumul
longterm
although
show
increas
hepat
steatosi
consequ
overexpress
data
indic
elev
hepat
lipid
accumul
mice
secondari
effect
alter
hepat
insulin
sensit
ii
energi
homeostasi
via
interfer
incretin
axi
mice
display
sever
hepat
insulin
resist
week
age
insulin
toler
test
indic
impair
insulin
sensit
alreadi
younger
age
fact
human
cell
murin
primari
hepatocyt
show
impair
insulin
sensit
respons
lead
conclus
direct
incretinindepend
effect
hepat
insulin
signal
insulinstimul
aktphosphoryl
blunt
treatment
recombin
well
adenovir
transgen
overexpress
importantli
dose
recombin
protein
induc
insulin
resist
ngml
physiolog
rang
found
serum
obes
insulin
resist
subject
observ
effect
insulin
sensit
independ
lipid
content
exclud
lipotoxicityinduc
insulin
resist
line
recent
publish
data
show
improv
insulin
sensit
lower
fat
content
cell
sirnamedi
suppress
furthermor
studi
primari
human
adipocyt
show
insulin
resist
administr
recombin
improv
insulin
sensit
downregul
moreov
longterm
inhibit
improv
insulin
sensit
reduc
liver
fat
content
anim
dietinduc
hepat
steatosi
insulin
resist
thu
autocrin
effect
hepat
insulin
signal
might
contribut
later
accumul
ectop
fat
liver
known
involv
energi
homeostasi
anorex
action
brain
show
mice
exhibit
lower
level
activ
peripheri
wherea
portal
vein
concentr
affect
clearli
demonstr
despit
normal
secret
intestin
lcell
hepat
overexpress
lead
substanti
reduct
activ
liver
passag
suggest
hepat
major
contributor
degrad
postprandi
sinc
hepat
express
usual
confin
bile
canalicular
domain
unlik
reach
bloodstream
degrad
howev
condit
liver
damag
polar
cell
chang
lead
releas
interstiti
fluid
describ
thu
increas
plasma
activ
mice
seem
sole
result
elev
express
also
chang
cell
polar
suppos
histolog
examin
figur
line
human
studi
shown
associ
serum
marker
liver
damag
ggt
alt
well
hepatocyt
fibrosi
apoptosi
contrast
rat
reveal
lower
serum
ast
alt
month
western
diet
mice
display
less
liver
fibrosi
inflamm
experiment
model
liver
injuri
show
hepatocytespecif
overexpress
result
signific
higher
level
ggt
numer
increas
ast
alt
concentr
provid
evid
direct
connect
hepat
liver
damag
observ
hypercholesterolemia
mice
line
previou
studi
show
increas
cholesterol
level
human
subject
elev
hepat
reduc
plasma
cholesterol
level
rat
elev
triglycerid
content
liver
mice
appear
consequ
augment
level
pparg
implic
liver
steatosi
similarli
exogen
increas
lipid
accumul
pparg
express
preadipocyt
activ
surfac
macrophag
middl
east
respiratori
syndrom
corona
viru
merscov
induc
pparg
express
hand
identifi
pparg
target
gene
cell
deriv
human
placent
tissu
mechan
pparg
induct
still
unclear
wherea
effect
increas
hepat
pparg
well
understood
hepatocytespecif
express
pparg
associ
fatti
liver
human
mice
hepat
overexpress
pparg
induc
liver
steatosi
wherea
ppargknockout
reduc
hepat
fat
content
mice
hfd
major
target
pparg
liver
fatti
acid
monoacylglycerol
oacyltransferas
implic
fatti
liver
diseas
upregul
liver
mice
thu
high
pparg
level
liver
seem
contribut
elev
level
hepat
steatosi
wronkowitz
colleagu
recent
identifi
proteaseactiv
receptor
receptor
implic
attenu
obes
adipos
tissu
inflamm
macrophag
infiltr
quantif
protein
content
depict
rel
tubulin
level
n
quantif
shown
figur
data
repres
mean
ae
sem
p
p
insulin
resist
shown
solubl
induc
inflamm
human
smooth
muscl
cell
via
mapk
nfkbmediat
pathway
studi
primari
human
adipocyt
reveal
suppress
tnfainduc
secret
genet
silenc
moreov
suggest
enhanc
inflammatori
action
upregul
tolllik
receptor
tlr
kidney
adipos
tissu
inhibit
antiinflammatori
effect
present
data
demonstr
increas
express
macrophag
marker
proinflammatori
cytokin
adipos
tissu
mice
despit
effect
adipos
express
sinc
elev
activ
circul
hepat
origin
like
hepat
contribut
induct
adipos
inflamm
via
tlrmediat
pathway
collect
present
studi
show
hepat
import
contributor
develop
nafld
condit
highfat
feed
overexpress
specif
hepatocyt
mice
result
hepat
insulin
resist
pronounc
liver
steatosi
find
demonstr
involv
regul
hepat
insulin
sensit
subsequ
lipid
storag
sole
marker
diseas
base
find
propos
applic
inhibitor
therapi
nafld
patient
order
improv
hepat
insulin
sensit
prevent
accumul
ectop
fat
liver
